Source: Virtual Congress 2020 – Non-tuberculous mycobacterial infections and bronchiectasis
Disease area: Airway diseases, Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
M. Crichton (Dundee (Angus), United Kingdom), M. Lonergan (Dundee (Angus), United Kingdom), A. Barker (Portland, United States of America), O. Sibila (Barcelona, Spain), P. Goeminne (Sint-Niklaas, Belgium), A. Shoemark (Dundee (Angus), United Kingdom), J. Chalmers (Dundee (Angus), United Kingdom). Inhaled antibiotics improve symptoms of cough and sputum in patients with bronchiectasis: a post-hoc analysis of the AIR-BX studies. 2365

Member's Comments

No comment yet.

Related content which might interest you: Sputum neutrophil elastase and inhaled antibiotic response in bronchiectasis: a post-hoc analysis of the ORBIT-4 trial Source: Virtual Congress 2021 – Bronchiectasis heterogeneity: assessing the endotypes Year: 2021 Long-term treatment with low-dose azithromycin reduces cough, sputum production and exacerbations in patients with idiopathic diffuse bronchiectasis Source: Eur Respir J 2004; 24: Suppl. 48, 707s Year: 2004 Bronchial challenge test in patients with chronic persistent cough and asthma Source: Eur Respir J 2003; 22: Suppl. 45, 475s Year: 2003 Significance of sputum purulence to guide antibiotic therapy in exacerbations of COPD Source: Eur Respir J 2013; 41: 248-249 Year: 2013 Significance of sputum purulence to guide antibiotic therapy in exacerbations of COPD Source: Eur Respir J 2013; 41: 248 Year: 2013 Clinical characteristics and outcomes of elderly patients with COPD: TIOSPIR® post-hoc analysis Source: International Congress 2016 – Novel avenues in the treatment of COPD II Year: 2016 Tolerance test for inhaled antibiotics in patients with chronic bronchial infection Source: International Congress 2018 – The airway microbiome across the spectrum of airway disease Year: 2018 Does having previous sputum results improve rationalisation of antimicrobial prescribing during acute exacerbations of COPD? Source: International Congress 2014 – Different interesting issues in respiratory infections: 2 Year: 2014 Changes in patients perception of dyspnoea, sputum volume and sputum purulence during treatment of chronic bronchitis exacerbations Source: Eur Respir J 2001; 18: Suppl. 33, 213s Year: 2001 Cost-minimisation analysis of two different inhaled steroids in persistent bronchial asthma Source: Eur Respir J 2002; 20: Suppl. 38, 302s Year: 2002 Once-daily QVA149 improves dyspnoea and health status compared with tiotropium plus formoterol in patients without ICS use: A post-hoc analysis of the QUANTIFY study Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015 The effect of twice-daily aclidinium bromide on cough and sputum in patients with COPD: Results from phase III studies Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 Effect of fluticasone furoate (FF)/vilanterol (VI) compared with VI on acute exacerbations of COPD (AECOPD): A post-hoc analysis by baseline airflow obstruction Source: International Congress 2015 – New data on established treatments for COPD Year: 2015 Microbiological indicators from sputum of patients with exacerbation of COPD Source: International Congress 2015 – Clinical issues in CAP: microbiological and radiological determinants Year: 2015 Oral antibiotics vs placebo for exacerbations of paediatric bronchiectasis Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: Intensive care and infection Year: 2019 Pulmonary targeted antibiotics in bronchiectasis; inhalers vs. nebulisers. A qualitative and quantitative assessment of patients’ attitudes Source: International Congress 2016 – Possible phenotypes of bronchiectasis and exacerbations Year: 2016 Effect of sputum bacteriology on the prognosis of patients with acute exacerbations of bronchiectasis Source: International Congress 2017 – COPD and weaning Year: 2017 Effect of extrafine medium strength (MS) ICS-containing triple therapy on exacerbations in asthmatics with persistent airflow limitation: A post-hoc analysis of the TRIMARAN study Source: International Congress 2019 – Asthma treatment: novel insights from clinical studies Year: 2019 Improvement in symptoms, wheezing and pulmonary function tests of asthmatic patients due to application of GINA in their treatment Source: Eur Respir J 2006; 28: Suppl. 50, 842s Year: 2006